Evidence map›Paper›PMID 42253304›Full record

ReviewPolymer science & technology (Washington, D.C.)2025

Bacterial Systems as a Precision Delivery Platform of Therapeutic Peptides for Cancer Therapy.

Jinyuan Liu, Guizhi Shen, Xuehai Yan

Abstract readReview
In one paragraph

Review in Polymer science & technology (Washington, D.C.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jinyuan LiuState Key Laboratory of Biochemical Engineering, Key Laboratory of Biopharmaceutical Preparation and Delivery, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, P. R. China.
Guizhi ShenState Key Laboratory of Biochemical Engineering, Key Laboratory of Biopharmaceutical Preparation and Delivery, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, P. R. China.
Xuehai YanState Key Laboratory of Biochemical Engineering, Key Laboratory of Biopharmaceutical Preparation and Delivery, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, P. R. China.ORCID https://orcid.org/0000-0002-0890-0340

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, peptide-based therapies have gained remarkable attention as promising tools for cancer treatment, offering notable advantages in specificity, modifiability, and reduced systemic toxicity. Various peptide classesincluding cell-penetrating, tumor-homing, pro-apoptotic, and immune-modulating peptideshave shown appreciable efficacy in selectively targeting cancer cells and modulating immune responses against tumors. Despite this potential, peptide therapies face significant challenges, such as susceptibility to rapid degradation, limited bioavailability, and inadequate accumulation within tumors. To address these issues, bacterial systems have emerged as innovative peptide delivery platforms, improving peptide stability, enhancing localized concentrations, and enabling controlled release directly at tumor sites. This review explores the synergistic potential of therapeutic peptides combined with bacterial delivery systems, with a focus on methods such as bacterial lysis for peptide release, secretion pathways, and peptide surface display. By harnessing the tumor-targeting properties and secretion capabilities of bacteria, these integrated approaches offer promising solutions to overcome the inherent limitations of peptide therapies, positioning them as advanced tools in precision oncology.

Indexed as

bacterial secretionbacterial surface displaycancer therapydirect bacterial lysisengineered bacterialtherapeutic peptides

Identifiers

PMID42253304
PMCPMC13052606

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.